Recombinant Collagenases for cell theraphy and regenerative medicine
Collagenase enzymes in Regenerative medicine are used to extract cells from biological tissues. Their challenging goal is to obtain a high number of living cells and reproducible results. Abiel patented technology platform fulfills these needs by synthesizing recombinant collagenases characterized by high stability and purity, allowing efficient, customized and standardized cell extraction procedures. Hence, the technology will support clinicians and companies in bringing cell therapies to the market, and will enable more patients to have access to cure for currently incurable diseases, thus releasing the huge economic burden these diseases cause on the healthcare systems worldwide.
State of development
- Biotechnology industrial application. Regarding the synthesis optimization we have so far reached a pre-industrial manufacturing process (synthesis-purification-lyophilization) that allows us producing up to 13 grams of high purity collagenases compared to 3-4g usually obtained through common fermentation processes.
- Current collagenases utilized for cell therapy are extracted from a pathogen bacterium and are a blend of different enzymes, which presents limitations in terms of reproducibility and standardization of protocols for cell isolation. Thanks to their properties, Abiel recombinant collagenases allow to optimize protocols and to obtain a high number of living cells every time. Therefore with this recombinant collagenases researchers and clinicians avoid to waste time and precious biological material
- Venture capital financing - Distribution Agreement - Industrial partnership